Medicus Pharma Ltd Common Stock
Yahoo Finance • 9 hours ago
Medicus To Continue Phase 2 For SkinJect In Carcinoma With FDA Recommendations; Stock Falls 12%
(RTTNews) - Medicus Pharma Inc. (MDCX), a biotech/life sciences company, on Tuesday announced the receipt of a 'Study May Proceed' notification from the U.S. Food and Drug Administration (FDA), allowing for the initiation of the Phase 2b S... Full story
Yahoo Finance • 2 days ago
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
PHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive t... Full story
Yahoo Finance • 13 days ago
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive t... Full story
Yahoo Finance • 29 days ago
Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology?
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Medicus Pharma Ltd. (NASDAQ:MDCX) is one of the best low-priced pharma stocks on this list. TheFly reported on June 15 that MDCX announced the filing of... Full story
Yahoo Finance • last month
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
PHILADELPHIA, June 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive t... Full story
Yahoo Finance • last month
Medicus Pharma Submits FDA Rare Pediatric Designation For SkinJect In Gorlin Syndrome
(RTTNews) - Medicus Pharma Ltd. (MDCX) on Monday announced the submission of a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration for SkinJect for the treatment of basal cell carcinoma in patients wi... Full story
Yahoo Finance • last month
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive t... Full story
Yahoo Finance • 2 months ago
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
PHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive t... Full story